<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="manner" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="cause" type="rst"/>
			<rel name="antithesis" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
			<rel name="sequence" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">4. Discussion</segment>
<segment id="2" parent="1003" relname="attribution">The present study confirms</segment>
<segment id="3" parent="1004" relname="span">that a remarkable number of patients with ACC</segment>
<segment id="4" parent="3" relname="elaboration">who are operated on with radical intent</segment>
<segment id="5" parent="1003" relname="same_unit">are destined to relapse .</segment>
<segment id="6" parent="1006" relname="preparation">ACC</segment>
<segment id="7" parent="1007" relname="joint">recurrence portends a worse prognosis</segment>
<segment id="8" parent="1007" relname="joint">and has a huge impact on quality of life ;</segment>
<segment id="9" parent="1009" relname="preparation">therefore , investigators have considered the use of adjuvant mitotane therapy following surgical operation .</segment>
<segment id="10" parent="1010" relname="span">However , a limited number of often small-sized studies</segment>
<segment id="11" parent="10" relname="elaboration">reporting the outcome of adjuvant mitotane is available .</segment>
<segment id="12" parent="1013" relname="span">In the present study , we explored the relationship between target mitotane concentrations and patient outcome</segment>
<segment id="13" parent="12" relname="means">using the TTR ,</segment>
<segment id="14" parent="1012" relname="same_unit">analogous to warfarin treatment .</segment>
<segment id="15" parent="1014" relname="span">Some previous studies used the peak mitotane level ,</segment>
<segment id="16" parent="1015" relname="joint">which cannot give an adequate representation</segment>
<segment id="17" parent="1016" relname="joint">since it is a measurement at a single point in time .</segment>
<segment id="18" parent="1019" relname="concession">In other studies , the percentage of mitotane measurements in a range was used ,</segment>
<segment id="19" parent="1019" relname="span">but this method has the caveat</segment>
<segment id="20" parent="19" relname="elaboration">of being strongly dependent on the number of available measurements .</segment>
<segment id="21" parent="1021" relname="span">This may introduce a bias</segment>
<segment id="22" parent="1022" relname="span">when comparing patients with different durations of follow-ups ,</segment>
<segment id="23" parent="22" relname="elaboration">which may be quite prolonged in the case of adjuvant therapy .</segment>
<segment id="24" parent="1024" relname="span">Moreover , there is no evidence</segment>
<segment id="25" parent="24" relname="purpose">to define what percentage level identifies a good exposure to mitotane .</segment>
<segment id="26" parent="1027" relname="span">These methodological issues may have contributed to the discrepancy in the literature</segment>
<segment id="27" parent="26" relname="elaboration">concerning adjuvant treatment .</segment>
<segment id="28" parent="1028" relname="span">In the present study , we calculated the TTR ,</segment>
<segment id="29" parent="1029" relname="joint">which in our opinion gives a more adequate representation of chronic exposure to mitotane ,</segment>
<segment id="30" parent="1030" relname="span">and analyzed the results in a multivariate analysis</segment>
<segment id="31" parent="30" relname="manner">without predefining arbitrary cutoff values .</segment>
<segment id="32" parent="1033" relname="joint">We found an inverse relationship between the TTR and risk of ACC recurrence ,</segment>
<segment id="33" parent="34" relname="attribution">implying</segment>
<segment id="34" parent="1035" relname="span">that the greater the TTR ,</segment>
<segment id="35" parent="1034" relname="same_unit">the lower the risk .</segment>
<segment id="36" parent="1033" relname="elaboration">This finding supports the clinical value of mitotane monitoring and the concept of target doses in the adjuvant setting .</segment>
<segment id="37" parent="1038" relname="attribution">Although it is plausible</segment>
<segment id="38" parent="1038" relname="same_unit">that lower mitotane concentrations may be effective in an adjuvant treatment ,</segment>
<segment id="39" parent="1039" relname="span">we analyzed only the level of 14 mg/L ,</segment>
<segment id="40" parent="39" relname="cause">because this was the target in our practice .</segment>
<segment id="41" parent="1041" relname="span">The time</segment>
<segment id="42" parent="41" relname="elaboration">needed</segment>
<segment id="43" parent="1043" relname="preparation">to achieve target mitotane concentrations also has an impact on the risk of ACC recurrence :</segment>
<segment id="44" parent="1044" relname="sequence">a longer time was associated with higher risk .</segment>
<segment id="45" parent="46" relname="attribution">This is consistent with the concept</segment>
<segment id="46" parent="1045" relname="span">that mitotane is a slow-acting drug in relation to the achievement of significant plasma levels .</segment>
<segment id="47" parent="1048" relname="span">Due to the very cautious dose titration in the starting phase of treatment</segment>
<segment id="48" parent="47" relname="elaboration">employed in many centers ,</segment>
<segment id="49" parent="1050" relname="span">the time</segment>
<segment id="50" parent="49" relname="elaboration">needed</segment>
<segment id="51" parent="1050" relname="purpose">to get into the target range was exceedingly long .</segment>
<segment id="52" parent="1053" relname="span">We identified a time point at 17 months</segment>
<segment id="53" parent="52" relname="purpose">to achieve target concentrations ,</segment>
<segment id="54" parent="1053" relname="elaboration">which significantly differentiates patients for their risk of recurrence .</segment>
<segment id="55" parent="1055" relname="span">The present findings call for a change in practice ,</segment>
<segment id="56" parent="1056" relname="joint">aiming for a faster rise in mitotane levels</segment>
<segment id="57" parent="1056" relname="joint">and strengthening the value of mitotane monitoring .</segment>
<segment id="58" parent="1059" relname="span">However , the potential danger of a rapid increment in mitotane dosing ,</segment>
<segment id="59" parent="58" relname="elaboration">which may result in important toxicity with consequent loss of compliance to treatment ,</segment>
<segment id="60" parent="1058" relname="same_unit">should be considered .</segment>
<segment id="61" parent="1061" relname="sequence">We found only a weak relationship between mitotane dose and its plasma concentrations during the first phase of treatment ,</segment>
<segment id="62" parent="1062" relname="span">and this finding is in agreement with the concept</segment>
<segment id="63" parent="62" relname="elaboration">that individual differences in mitotane metabolism and other still unknown factors influence plasma concentrations .</segment>
<segment id="64" parent="1064" relname="sequence">Interestingly , higher doses were employed in men and in patients with greater BMI</segment>
<segment id="65" parent="1065" relname="span">and these novel findings matter for clinical practice .</segment>
<segment id="66" parent="1067" relname="span">In our cohort , toxicity</segment>
<segment id="67" parent="66" relname="elaboration">associated with adjuvant mitotane was acceptable ,</segment>
<segment id="68" parent="1068" relname="span">though we acknowledge the fact</segment>
<segment id="69" parent="1069" relname="span">that due to the study inclusion criteria</segment>
<segment id="70" parent="1070" relname="span">we did not capture the patients</segment>
<segment id="71" parent="70" relname="elaboration">who eventually discontinued mitotane in the first six months .</segment>
<segment id="72" parent="1073" relname="span">Severe toxicity</segment>
<segment id="73" parent="72" relname="elaboration">leading to permanent treatment discontinuation was recorded in only five patients on chronic therapy ,</segment>
<segment id="74" parent="1074" relname="span">and this is likely due to the low doses</segment>
<segment id="75" parent="1076" relname="span">( median dose of 2 g/day )</segment>
<segment id="76" parent="75" relname="elaboration">used</segment>
<segment id="77" parent="1076" relname="purpose">to continue treatment in the maintenance phase .</segment>
<segment id="78" parent="1079" relname="attribution">Thus , the present study shows</segment>
<segment id="79" parent="1079" relname="span">that a few patients cannot tolerate adjuvant mitotane following the first months of treatment ,</segment>
<segment id="80" parent="1080" relname="span">proving</segment>
<segment id="81" parent="80" relname="antithesis">than a careful follow-up is necessary .</segment>
<segment id="82" parent="1083" relname="span">Despite mitotane having a reputation for being a challenging drug</segment>
<segment id="83" parent="82" relname="purpose">to manage ,</segment>
<segment id="84" parent="1084" relname="span">adjuvant mitotane treatment is feasible</segment>
<segment id="85" parent="84" relname="circumstance">when patients are managed in expert centers .</segment>
<segment id="86" parent="1086" relname="span">However , some patients were unable to tolerate the drug ,</segment>
<segment id="87" parent="1087" relname="span">exhibiting neurological toxicity</segment>
<segment id="88" parent="1088" relname="span">even when exposed to “ normal ” mitotane concentrations ,</segment>
<segment id="89" parent="88" relname="elaboration">confirming the relevance of individual factors in mitotane metabolism .</segment>
<segment id="90" parent="1090" relname="span">Strengths of the present study are the thorough characterization of adjuvant mitotane treatment of ACC patients</segment>
<segment id="91" parent="1091" relname="joint">following surgical removal of the tumor and the large data set ,</segment>
<segment id="92" parent="1091" relname="joint">considering the rarity of the disease .</segment>
<segment id="93" parent="1094" relname="span">This allowed for the capture of details of mitotane treatment</segment>
<segment id="94" parent="93" relname="elaboration">that were not available in previous studies</segment>
<segment id="95" parent="1096" relname="span">and led to observations</segment>
<segment id="96" parent="95" relname="elaboration">that may be useful</segment>
<segment id="97" parent="1096" relname="purpose">to informing future practice .</segment>
<segment id="98" parent="1098" relname="joint">However , we should acknowledge the limits of a retrospective analysis ,</segment>
<segment id="99" parent="1099" relname="span">and that our results are not generalizable to patients</segment>
<segment id="100" parent="99" relname="elaboration">who discontinue treatment within six months for intolerability or patients with early ACC recurrence .</segment>
<segment id="101" parent="1100" relname="span">The inclusion criteria of the study produced an immortal time of six months</segment>
<segment id="102" parent="1101" relname="span">that may have enriched our series of a higher number of low-risk ACC</segment>
<segment id="103" parent="102" relname="elaboration">compared to recently published series .</segment>
<group id="1000" type="span" />
<group id="1001" type="multinuc" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1001" relname="joint"/>
<group id="1003" type="multinuc" parent="1002" relname="span"/>
<group id="1004" type="span" parent="1003" relname="same_unit"/>
<group id="1005" type="span" parent="1001" relname="joint"/>
<group id="1006" type="span" parent="1005" relname="span"/>
<group id="1007" type="multinuc" parent="1008" relname="preparation"/>
<group id="1008" type="span" parent="1006" relname="span"/>
<group id="1009" type="multinuc" parent="1008" relname="span"/>
<group id="1010" type="span" parent="1009" relname="joint"/>
<group id="1012" type="multinuc" parent="1009" relname="joint"/>
<group id="1013" type="span" parent="1012" relname="same_unit"/>
<group id="1014" type="span" parent="1009" relname="joint"/>
<group id="1015" type="multinuc" parent="15" relname="elaboration"/>
<group id="1016" type="multinuc" parent="1015" relname="joint"/>
<group id="1017" type="multinuc" parent="1016" relname="joint"/>
<group id="1018" type="span" parent="1017" relname="joint"/>
<group id="1019" type="span" parent="1018" relname="span"/>
<group id="1020" type="multinuc" parent="1017" relname="joint"/>
<group id="1021" type="span" parent="1020" relname="joint"/>
<group id="1022" type="span" parent="21" relname="circumstance"/>
<group id="1023" type="multinuc" parent="1020" relname="joint"/>
<group id="1024" type="span" parent="1023" relname="joint"/>
<group id="1025" type="multinuc" parent="1023" relname="joint"/>
<group id="1026" type="span" parent="1025" relname="sequence"/>
<group id="1027" type="span" parent="1026" relname="span"/>
<group id="1028" type="span" parent="1027" relname="elaboration"/>
<group id="1029" type="multinuc" parent="28" relname="elaboration"/>
<group id="1030" type="span" parent="1029" relname="joint"/>
<group id="1031" type="multinuc" parent="1025" relname="sequence"/>
<group id="1032" type="span" parent="1031" relname="joint"/>
<group id="1033" type="multinuc" parent="1032" relname="span"/>
<group id="1034" type="multinuc" parent="1033" relname="joint"/>
<group id="1035" type="span" parent="1034" relname="same_unit"/>
<group id="1036" type="multinuc" parent="1031" relname="joint"/>
<group id="1037" type="span" parent="1036" relname="sequence"/>
<group id="1038" type="multinuc" parent="1037" relname="span"/>
<group id="1039" type="span" parent="1038" relname="same_unit"/>
<group id="1040" type="span" parent="1036" relname="sequence"/>
<group id="1041" type="span" parent="1042" relname="preparation"/>
<group id="1042" type="span" parent="1040" relname="span"/>
<group id="1043" type="multinuc" parent="1042" relname="span"/>
<group id="1044" type="multinuc" parent="1043" relname="joint"/>
<group id="1045" type="span" parent="1044" relname="sequence"/>
<group id="1046" type="multinuc" parent="1043" relname="joint"/>
<group id="1047" type="multinuc" parent="1046" relname="joint"/>
<group id="1048" type="span" parent="1047" relname="same_unit"/>
<group id="1049" type="span" parent="1047" relname="same_unit"/>
<group id="1050" type="span" parent="1049" relname="span"/>
<group id="1051" type="span" parent="1046" relname="joint"/>
<group id="1052" type="span" parent="1054" relname="preparation"/>
<group id="1053" type="span" parent="1052" relname="span"/>
<group id="1054" type="multinuc" parent="1051" relname="span"/>
<group id="1055" type="span" parent="1054" relname="contrast"/>
<group id="1056" type="multinuc" parent="55" relname="elaboration"/>
<group id="1057" type="multinuc" parent="1054" relname="contrast"/>
<group id="1058" type="multinuc" parent="1057" relname="joint"/>
<group id="1059" type="span" parent="1058" relname="same_unit"/>
<group id="1060" type="multinuc" parent="1057" relname="joint"/>
<group id="1061" type="multinuc" parent="1060" relname="joint"/>
<group id="1062" type="span" parent="1061" relname="sequence"/>
<group id="1063" type="multinuc" parent="1060" relname="joint"/>
<group id="1064" type="multinuc" parent="1063" relname="joint"/>
<group id="1065" type="span" parent="1064" relname="sequence"/>
<group id="1066" type="span" parent="65" relname="elaboration"/>
<group id="1067" type="span" parent="1066" relname="span"/>
<group id="1068" type="span" parent="1067" relname="concession"/>
<group id="1069" type="span" parent="68" relname="elaboration"/>
<group id="1070" type="span" parent="69" relname="elaboration"/>
<group id="1071" type="multinuc" parent="1063" relname="joint"/>
<group id="1072" type="multinuc" parent="1071" relname="joint"/>
<group id="1073" type="span" parent="1072" relname="joint"/>
<group id="1074" type="span" parent="1072" relname="joint"/>
<group id="1075" type="span" parent="74" relname="elaboration"/>
<group id="1076" type="span" parent="1075" relname="span"/>
<group id="1077" type="multinuc" parent="1071" relname="joint"/>
<group id="1078" type="span" parent="1077" relname="joint"/>
<group id="1079" type="span" parent="1078" relname="span"/>
<group id="1080" type="span" parent="79" relname="elaboration"/>
<group id="1081" type="span" parent="1077" relname="joint"/>
<group id="1082" type="span" parent="1085" relname="concession"/>
<group id="1083" type="span" parent="1084" relname="concession"/>
<group id="1084" type="span" parent="1082" relname="span"/>
<group id="1085" type="multinuc" parent="1081" relname="span"/>
<group id="1086" type="span" parent="1085" relname="joint"/>
<group id="1087" type="span" parent="86" relname="elaboration"/>
<group id="1088" type="span" parent="87" relname="concession"/>
<group id="1089" type="multinuc" parent="1085" relname="joint"/>
<group id="1090" type="span" parent="1089" relname="joint"/>
<group id="1091" type="multinuc" parent="90" relname="elaboration"/>
<group id="1092" type="multinuc" parent="1089" relname="joint"/>
<group id="1093" type="multinuc" parent="1092" relname="contrast"/>
<group id="1094" type="span" parent="1093" relname="joint"/>
<group id="1095" type="span" parent="1093" relname="joint"/>
<group id="1096" type="span" parent="1095" relname="span"/>
<group id="1097" type="multinuc" parent="1092" relname="contrast"/>
<group id="1098" type="multinuc" parent="1097" relname="joint"/>
<group id="1099" type="span" parent="1098" relname="joint"/>
<group id="1100" type="span" parent="1097" relname="joint"/>
<group id="1101" type="span" parent="101" relname="elaboration"/>
	</body>
</rst>
